Rohto Pharmaceutical announced its first-quarter results for the fiscal year ending March 2027 and an upward revision of its full-year forecast, sending its stock price surging by 500 yen to 2,862.5 yen on August 7, the following day. In the first quarter, revenue rose 11.8 percent year-on-year to 91.6 billion yen, and operating profit grew 16.8 percent to 13.6 billion yen, marking increases in both revenue and profit. However, ordinary profit fell 10.1 percent to 14.4 billion yen, and net profit declined 9.5 percent to 10.6 billion yen. The company explained that this was due to a reaction from one-time dividend income recorded in the same period a year earlier, and not a slowdown in its core business. At the same time, it revised its full-year forecast upward, now projecting revenue of 372.3 billion yen, up 8.3 percent from the previous year, operating profit of 45 billion yen, up 9.4 percent, and net profit of 35.2 billion yen, up 2.8 percent. The upward revision was attributed to stronger-than-expected performance across Asia, Japan, and Europe, as well as a review of assumed exchange rates. The market appears to have focused on the full-year profit growth outlook rather than the one-off profit decline.
Rohto Pharmaceutical Co., Ltd.Upward revision of full-year forecast and strong Q1 results drive stock surge.
